Neurogene Incis A Clinical Stage Biotechnology Company Based In New York Cityfocused On Developing Genetic Medicines For Rare Neurological Diseasesfounded In 2003The Company Is Dedicated To Addressing Unmet Medical Needs Through Innovative Gene Therapieswith A Team Of 107 Employeesneurogene Is Led By Ceo Rachel Mcminn And Emphasizes Scientific Execution And Purpose Driven Innovation The Company S Pipeline Includes Ngn 401An Investigational Gene Therapy For Rett Syndromeand Ngn 101A Gene Therapy Candidate For Cln5 Batten Diseaseboth Currently In Phase 1 2 Trialsneurogene Utilizes Its Proprietary Exacta C Technology To Enable Precise Control Of Therapeutic Gene Expressionwhich Is Essential For Treating Dosage Sensitive Neurological Conditionsthe Company Collaborates With Institutions Like The University Of Edinburgh And Has Licensing Agreements With Viroveksigma Aldrichand Stanford University To Support Its Gene Therapy Development Efforts
No conferences found for this company.
| Company Name | Neurogeneration Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
